Chronic Obstructive Pulmonary Disease Drugs Market Size to grow by USD 6654.49 million between 2023-2027
According to a research report “ Chronic Obstructive Pulmonary Disease Drugs Market” by Product (Combination therapy, Monotherapy) Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2027 published by Technavio, the market size is estimated to grow by USD 6654.49 million, at a CAGR of 6.09% during the forecast period. Chronic Obstructive Pulmonary Disease (COPD) is a leading non-communicable disease with significant global prevalence, primarily driven by lifestyle factors such as smoking and exposure to biomass fuel and air pollution. According to Natalie Terzikhan et al., COPD is the third-leading cause of death worldwide, with smoking being the primary risk factor, particularly in developed countries where cigarette use is prevalent. Tobacco smoke acts as an irritant, damaging the bronchi and alveoli in the lungs, ultimately leading to COPD's progressive deterioration. The global burden of COPD necessitates continuous research and development of effective treatment and management strategies.
Browse market data tables, figures, and in-depth TOC on “Chronic Obstructive Pulmonary Disease Drugs Market” by Product (Combination therapy, Monotherapy) Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2027. Download Free Sample
By Product, the Combination therapy segment is projected to dominate the market size in 2024
In the Chronic Obstructive Pulmonary Disease (COPD) drugs market, hospital pharmacies represent a significant distribution channel. These establishments procure pharmaceuticals directly from pharmaceutical companies for both outpatient and inpatient use. Hospital pharmacies house a range of therapeutic and critical care drugs, applicable to various medical disciplines such as cardiology, neurology, urology, and pathogenic infections. The primary objective of hospital pharmacies is to manage the acquisition, storage, and distribution of medications within healthcare facilities. During a patient's hospitalization, these drugs are administered as part of their treatment regimen. Hospital pharmacies have gained prominence as the preferred distribution channel for compounded COPD drugs, holding the largest market share in 2022 and expected to maintain this position throughout the forecast period.
By Distribution Channel, Hospital pharmacies segment is expected to hold the largest market size for the year 2024
In the Chronic Obstructive Pulmonary Disease (COPD) market, combination therapy has emerged as an effective treatment approach, utilizing two or more therapeutic agents concurrently. Leading pharmaceutical companies have developed single-dose formulations by combining two to three distinct drug classes for optimized COPD management. Notable combination therapy drugs in the global COPD drugs market include SYMBICORT, TRELEGY ELLIPTA, BREO ELLIPTA, SERETIDE ADVAIR, UTIBRON NEOHALER, and BEVESPI AEROSPHERE. These innovative treatments offer multiple pharmacologic benefits, with several high-efficacy combinations of novel bronchodilators receiving approval for COPD treatment over the past decade.
North America is forecasted to hold the largest market size by region in 2024
The COPD drugs market in North America is experiencing significant growth, driven by three key factors. Firstly, the increasing prevalence of COPD, with over 16 million people in the US diagnosed with the condition in 2020, according to the National Institutes of Health. Secondly, the availability of reimbursement schemes facilitates patient access to COPD treatments. Lastly, approvals for new triple combination drugs expand the therapeutic options for COPD patients, further fueling market expansion.
The Chronic Obstructive Pulmonary Disease Drugs Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:
.
For insights on company offerings- Request a sample report!
Research Analysis Overview
Chronic Obstructive Pulmonary Disease (COPD) is a chronic disease that requires specialized treatment and long-term care. COPD management focuses on improving quality of life, disease outcomes, and slowing down disease progression. Traditional treatment approaches include bronchodilators, corticosteroids, and oxygen therapy. However, innovative therapies such as pulmonary rehabilitation, lung volume reduction surgery, and lung transplantation are also effective. COPD is often caused by indoor air pollution, workplace pollution, and smoking tobacco. The disease burden is particularly high in underdeveloped and developing countries due to high levels of indoor air pollution and tobacco consumption. Recognition and diagnosis of COPD are crucial for effective treatment, and medical knowledge and diagnostic tools continue to advance. Governments and healthcare systems play a significant role in COPD management by investing in research, treatments, and diagnostic tools. Expenditure on healthcare for COPD is expected to increase due to the aging population and rising tobacco consumption among the youth. Generic drugs offer an affordable alternative to expensive branded medications, making COPD treatment more accessible. Innovative therapies, such as gene therapy and stem cell therapy, are under investigation to provide better treatment options for COPD patients. Overall, continued research and investment in COPD management are essential to improve outcomes and reduce the burden of this chronic disease.
Market Research Overview
Chronic Obstructive Pulmonary Disease (COPD) is a progressive and debilitating medical condition that affects the lungs, causing obstruction in airflow and impaired breathing. With patent expiry of key COPD drugs, the market is witnessing an influx of biosimilars and generic drugs, making treatments more affordable for patients. However, lack of knowledge about COPD symptoms and underdiagnoses remain a concern, especially in developing countries. COPD is primarily caused by smoking tobacco, exposure to indoor air pollution, workplace pollution, and genetic factors like alpha-1-antitrypsin deficiency. The disease burden is high, with COPD being the third leading cause of death worldwide. The pharmaceutical industry and governments are investing in research and treatments for COPD, including innovative therapies and diagnostic tools. COPD treatment costs are a significant expenditure on healthcare, especially in chronic disease management, long-term care, and specialized treatment. Comorbidities like asthma, lung cancer, and cardiovascular diseases further increase healthcare costs. Understanding the importance of early diagnosis and proper COPD management can lead to improved patient outcomes, better quality of life, and disease progression prevention. Lifestyle changes, such as quitting smoking and avoiding exposure to pollutants, are essential in COPD management. Governments and healthcare systems in underdeveloped and developing countries need to invest in COPD awareness, diagnosis, and treatment to reduce the disease burden and improve the quality of life for affected populations.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
